Research

Hormonal

Next-generation incretin-based therapies (GLP-1 RAs like semaglutide and dual GLP-1/GIP agonists like tirzepatide) significantly reduce blood pressure and improve cardiovascular outcomes in patients with hypertension, obesity, or type 2 diabetes, acting through both weight loss and direct tissue effects on the cardiovascular system.

If you have high blood pressure, obesity, or type 2 diabetes, ask your doctor about GLP-1 or GLP-1/GIP medications like semaglutide or tirzepatide. These weekly injections not only help with weight loss but also directly lower blood pressure and protect your heart, often allowing you to reduce or stop other blood pressure medications. The benefits extend beyond weight loss through direct effects on your blood vessels and nervous system.

GoodSupportsHIGH confidence
These drugs not only promote weight loss but also substantially lower blood pressure (BP) and reduce cardiovascular end points.
Leonie Dreher et al. · Hypertension · 2025

Why this rating

Based on large, placebo-controlled trials (SELECT, SUSTAIN, STEP, SURPASS) with hard cardiovascular endpoints, though BP was rarely the primary endpoint.

Source

Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?

Leonie Dreher et al. · Hypertension · 2025

DOI 10.1161/hypertensionaha.125.25112

narrative_reviewCited 8×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →